Losartan, a therapeutic candidate in congenital muscular dystrophy: Studies in the <i>dy^2J/dy^2J</i> Mouse

Abstract

Losartan, a commonly prescribed US Food and Drug Administration-approved medication for hypertension, demonstrated clinical improvement and amelioration of fibrosis in the dy(2J) /dy(2J) mouse model of MDC1A via TGF-β and MAPK signaling pathways. The results of this study support pursuing a clinical trial of losartan treatment in children with MDC1A.